Woodline Partners’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Woodline Partners’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$252K	–	926
2022 Q4	$252K	Hold	25,000	–	–	﹤0.01%	667
2022 Q3	$248K	Buy	+25,000	New	+$247K	﹤0.01%	635

Woodline Partners's BIOT Position: Q1 2023 in Review

Woodline Partners sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 25,000 shares — an estimated $252K sold.

Woodline Partners first reported a position in BIOT in Q3 2022 and held it in 2 quarters. The position peaked at $252K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Woodline Partners reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Woodline Partners sold 25,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $252K.
Woodline Partners first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2022 and held it in 2 quarters.
Woodline Partners's Biotech Acquisition Company Class A Ordinary Shares position peaked at $252K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.